Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Ameriprise Financial Inc.

Ameriprise Financial Inc. trimmed its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 70.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 51,076 shares of the company’s stock after selling 124,245 shares during the quarter. Ameriprise Financial Inc. owned about 0.07% of Kiniksa Pharmaceuticals worth $1,010,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS acquired a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter worth $158,000. Tower Research Capital LLC TRC lifted its position in Kiniksa Pharmaceuticals by 117.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company’s stock valued at $168,000 after purchasing an additional 4,575 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Kiniksa Pharmaceuticals by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock valued at $174,000 after purchasing an additional 1,004 shares during the period. Teacher Retirement System of Texas lifted its holdings in shares of Kiniksa Pharmaceuticals by 7.1% in the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company’s stock valued at $215,000 after buying an additional 719 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter valued at approximately $258,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Kiniksa Pharmaceuticals

In related news, CAO Michael R. Megna sold 9,051 shares of the company’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the completion of the transaction, the chief accounting officer now directly owns 26,528 shares in the company, valued at approximately $595,553.60. This represents a 25.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Ross Moat sold 18,259 shares of the company’s stock in a transaction on Monday, April 21st. The shares were sold at an average price of $20.29, for a total value of $370,475.11. Following the completion of the transaction, the insider now owns 9,415 shares of the company’s stock, valued at $191,030.35. The trade was a 65.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 329,910 shares of company stock valued at $8,336,038. 54.57% of the stock is owned by insiders.

Kiniksa Pharmaceuticals Trading Up 0.9%

KNSA stock opened at $27.43 on Monday. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -195.91 and a beta of 0.07. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $17.38 and a 12-month high of $28.56. The firm has a 50 day moving average of $23.62 and a 200-day moving average of $21.63.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. During the same period in the previous year, the firm posted ($0.25) EPS. The company’s quarterly revenue was up 72.5% compared to the same quarter last year. Sell-side analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on KNSA. Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, April 29th. Citigroup initiated coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.00 target price for the company. Finally, Wedbush reissued an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $38.80.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.